Novelty Nobility
A private biotech company focused on the research of novel angiogenesis targets and develop antibody-based therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | N/A | KRW74.4b | Series C |
| Total Funding | 000k | ||
Related Content
Novelty Nobility Inc. is a private biotech company headquartered in South Korea, specializing in the design, discovery, optimization, and early-stage development of next-generation antibodies. The company focuses on creating therapeutic antibodies, antibody drug conjugates (ADCs), and ADC linker technologies to address drug resistance, primarily in oncology. However, they also explore other medical fields such as ophthalmology and autoimmune diseases to meet unmet medical needs.
The company serves pharmaceutical and biotechnology firms looking for innovative solutions in antibody development. Operating in the highly specialized biotech market, Novelty Nobility employs a business model centered around research and development, partnering with other firms for clinical trials and commercialization. Revenue is generated through licensing agreements, research collaborations, and milestone payments.
Keywords: therapeutic antibodies, ADCs, drug resistance, oncology, biotechnology, antibody design, South Korea, research and development, licensing, innovation.